reports
Tetraphase Pharmaceuticals Inc: 1 director sold
A director at Tetraphase Pharmaceuticals Inc sold 15,031 shares at 2.190USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success...
Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference WATERTOWN, Mass., Dec. 05, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that President and Chief Executive Officer Guy Macdonald will present a corporate overview at the BMO Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018 at 9:40 a.m. ET at the Mandarin Oriental Hotel in New York City. A live audio webca...
Tetraphase Pharmaceuticals Reports Third Quarter 2018 Financial Result...
Tetraphase Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update XERAVATM (eravacycline) Now Available to Hospitals in the United States Conference Call Today at 4:30 p.m. Eastern Time WATERTOWN, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the quarter ended September 30, 2018 and provided a corporate update. “During the third quarter of 2018, we reach...
Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences WATERTOWN, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that President and Chief Executive Officer Guy Macdonald will present a corporate overview at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 8:00 a.m. ET at Lotte New York Palace Hotel in New York City. Mr. Macdonald also will participate in a fireside chat at t...
Tetraphase Pharmaceuticals to Host Third Quarter 2018 Financial Result...
Tetraphase Pharmaceuticals to Host Third Quarter 2018 Financial Results Conference Call WATERTOWN, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will host a conference call at 4:30 p.m. ET on Thursday, November 8, 2018 to discuss third quarter financial results and provide a general corporate update. The conference call may be accessed by dialing 844-831-4023 (U.S. and Canada) or 731-256-...
Tetraphase Pharmaceuticals Announces Positive Data from Post-Hoc Analy...
Tetraphase Pharmaceuticals Announces Positive Data from Post-Hoc Analysis of Phase 3 Trials Demonstrating Efficacy of XERAVA™ (eravacycline) in Obese and Renally Impaired Patients with Complicated Intra-Abdominal Infections WATERTOWN, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, announced data from two post-hoc analyses of pooled data from two Phase 3 IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) stu...
Tetraphase Pharmaceuticals Announces Commercial Launch of XERAVA™ i...
Tetraphase Pharmaceuticals Announces Commercial Launch of XERAVA™ in the United States FDA-Approved for the Treatment of Complicated Intra-Abdominal Infections Provides Broad Spectrum of Coverage Against Gram-negative, Gram-positive, and Anaerobic Bacteria for a Range of Patients with Empiric and Confirmed Infections WATERTOWN, Mass., Oct. 11, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced the U.S. commercial launch of XERAVA™...
Tetraphase Pharmaceuticals Announces Presentation of Positive Data fro...
Tetraphase Pharmaceuticals Announces Presentation of Positive Data from Phase 3 Trials of XERAVA™ (eravacycline) and Multiple-Ascending Dose Trial of TP-6076 at IDWeek 2018 XERAVA Demonstrated Efficacy in Treating Secondary Bacteremia in Patients with Complicated Intra-Abdominal Infections in Post-Hoc Analysis of Phase 3 Clinical Trials TP-6076 Demonstrated Favorable Pharmacokinetic and Safety Profile in Phase 1 Trial, Supporting Advancement into a Bronchopulmonary Disposition Study WATERTOWN, Mass., Oct. 08, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company ...
Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Li...
Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) WATERTOWN, Mass., Sept. 28, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that Tetraphase's Compensation Committee of the Board of Directors approved, pursuant to NASDAQ Listing Rule 5635(c)(4), the grant of inducement equity awards in the form of stock options to over thirty new sales employees to purchase an aggregate of 128,250 shares ...
Tetraphase Pharmaceuticals to Present at the Cantor Global Healthcare ...
Tetraphase Pharmaceuticals to Present at the Cantor Global Healthcare Conference WATERTOWN, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that President and Chief Executive Officer Guy Macdonald will present a corporate overview at the Cantor Global Healthcare Conference on Monday, October 1, 2018 at 5:15 p.m. Eastern Time at InterContinental New York Barclay Hotel in New York City. A live webcast of the presen...
Tetraphase Pharmaceuticals Announces Adoption of Commission Decision G...
Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections – Broad Product Label for Treatment of Complicated Intra-Abdominal Infections – – Phased Commercial Launch Expected in the First Half of 2019 – WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today an...
Tetraphase Pharmaceuticals to Present XERAVAâ„¢ (Eravacycline) and TP-...
Tetraphase Pharmaceuticals to Present XERAVA™ (Eravacycline) and TP-6076 Data at IDWeek 2018 – Four Abstracts Selected for Poster Presentations – – TP-6076 Featured in Oral Presentation – WATERTOWN, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced it will have four posters and one oral presentation at the Infectious Disease Society of America’s (IDSA) Infectious Disease Week (IDWeek) 2018, taking place October 3...
Tetraphase Pharmaceuticals Announces FDA Approval of XERAVAâ„¢ (Eravac...
Tetraphase Pharmaceuticals Announces FDA Approval of XERAVA™ (Eravacycline) for Complicated Intra-Abdominal Infections (cIAI) – XERAVA™ Achieved High Clinical Cure Rates in Clinical Trials in Patients with cIAI – – Broad Product Label for Treatment of cIAI – – Commercial Launch Expected in the Fourth Quarter of 2018 – – Conference Call Scheduled for Today at 4:30 p.m. ET – WATERTOWN, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infecti...
CORRECTING and REPLACING -- Tetraphase Pharmaceuticals to Participate ...
CORRECTING and REPLACING -- Tetraphase Pharmaceuticals to Participate at Upcoming Investor Conference WATERTOWN, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- In a release issued earlier today by Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) please note that the upcoming investor conference details have been updated. The corrected release follows: (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at th...
Tetraphase Pharmaceuticals Reports Second Quarter 2018 Financial Resul...
Tetraphase Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Highlights WATERTOWN, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the second quarter ended June 30, 2018. “In the second quarter of 2018, we moved closer to achieving our goal to bring XeravaTM (eravacycline) to market on a global level as an important new antibiotic for patients with serious, often life-th...
Tetraphase Pharmaceuticals Receives Positive CHMP Opinion for Xeravaâ„...
Tetraphase Pharmaceuticals Receives Positive CHMP Opinion for Xerava™ (eravacycline) as a Treatment for Complicated Intra-Abdominal Infections WATERTOWN, Mass., July 27, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending Xerava (eravacycline) for approval as a treatment for adult patients with ...
Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Li...
Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) WATERTOWN, Mass., July 12, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that Tetraphase's Compensation Committee of the Board of Directors approved, pursuant to NASDAQ Listing Rule 5635(c)(4), the grant of inducement equity awards in the form of stock options to four new employees to purchase an aggregate of 60,000 shares of Tetraphase's...
Tetraphase Pharmaceuticals Announces Data from a Pooled Analysis of IG...
Tetraphase Pharmaceuticals Announces Data from a Pooled Analysis of IGNITE1 and IGNITE4 Phase 3 Trials Evaluating Eravacycline in Complicated Intra-Abdominal Infections at the ASM Microbe 2018 Annual Meeting Eravacycline Global Surveillance and TP-6076 Data Also Highlighted WATERTOWN, Mass., June 11, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, recently reported data on eravacycline, which is currently under review by the United States Food ...
Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Li...
Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) WATERTOWN, Mass., June 08, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that Tetraphase's Compensation Committee of the Board of Directors approved, pursuant to NASDAQ Listing Rule 5635(c)(4), the grant of inducement equity awards in the form of stock options to four new employees to purchase an aggregate of 60,000 shares of Tetraphase's...
INVESTOR ALERT: Investigation of Tetraphase Pharmaceuticals Announced ...
ATLANTA--(BUSINESS WIRE)-- Holzer & Holzer, LLC is investigating whether Tetraphase Pharmaceuticals, Inc. (“Tetraphase” or the “Company”) (NASDAQ: TTPH) complied with the federal securities laws. On February 13, 2018, Tetraphase announced that its IGNITE3 clinical trial did not achieve its co-primary endpoints of responder rate at the end of treatment and test-of-cure visit. The price of Tetraphase stock fell significantly following the announcement. If you purchased Tetraphase common stock and suffered a loss on that ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.